Coherus Oncology (CHRS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
27 May, 2026Opening remarks and agenda
The meeting was called to order virtually, with stockholders attending via a web portal and rules of conduct provided for orderly proceedings.
The agenda included five proposals: election of directors, ratification of the auditor, advisory vote on executive compensation, increase in equity plan shares, and a proposal on stock option exercise price reduction.
Board and executive committee updates
Two Class III directors, Dennis M. Lanfear and Mats L. Wahlström, were nominated to serve until the 2029 Annual Meeting.
No advance notice of alternative director nominations was received from stockholders.
Shareholder proposals
Proposals included electing directors, ratifying the auditor, approving executive compensation, and increasing shares under the equity plan.
The proposal to reduce the exercise price of certain stock options was adjourned to a later date to ensure all votes are counted.
Latest events from Coherus Oncology
- Q2 2026 revenue rose up to 40% year-over-year, but ongoing losses and funding needs persist.CHRS
Q2 2026 - Advancing innovative oncology assets with strong early data and robust financial backing.CHRS
The Citizens JMP Life Sciences Conference 2025 - Immuno-oncology focus drives LOQTORZI growth and pipeline progress, with key milestones ahead.CHRS
H.C. Wainwright 27th Annual Global Investment Conference - Immuno-oncology pipeline advances with key data and global deals expected in 6–18 months.CHRS
Jefferies Global Healthcare Conference 2026 - Voting on repricing stock options was adjourned and will reconvene to finalize Proposal 4.CHRS
Proxy filing - LOQTORZI sales surged 61% year-over-year as net losses narrowed and cash reserves remained strong.CHRS
Q1 2026 - Key vote on repricing employee stock options set for May 27, 2026 annual meeting.CHRS
Proxy filing - Five key proposals, including director elections and equity plan changes, up for shareholder vote.CHRS
Proxy filing - Shareholders to vote on repricing employee stock options at the May 2026 virtual meeting.CHRS
Proxy filing